Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03064113




Registration number
NCT03064113
Ethics application status
Date submitted
20/01/2017
Date registered
24/02/2017
Date last updated
24/02/2022

Titles & IDs
Public title
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease
Secondary ID [1] 0 0
ACTRN12611000482965
Secondary ID [2] 0 0
0059
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease, COPD 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Sequence 1 - Period 1 = Placebo; Period 2 = TD-4208 700 µg; Period 3 = TD-4208 350 µg; Period 4 = Ipratropium 500 µg

Experimental: Sequence 2 - Period 1 = TD-4208 700 µg; Period 2 = Ipratropium 500 µg; Period 3 = Placebo; Period 4 = TD-4208 350 µg

Experimental: Sequence 3 - Period 1 = TD-4208 350 µg; Period 2 = Placebo; Period 3 = Ipratropium 500 µg; Period 4 = TD-4208 700 µg

Experimental: Sequence 4 - Period 1 = Ipratropium 500 µg; Period 2 = TD-4208 350 µg; Period 3 = TD-4208 700 µg; Period 4 = Placebo
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline
Timepoint [1] 0 0
From predose to 25 hours postdose
Secondary outcome [1] 0 0
Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo
Timepoint [1] 0 0
12 hr and 24 hr
Secondary outcome [2] 0 0
Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo
Timepoint [2] 0 0
12 hr and 24 hr
Secondary outcome [3] 0 0
Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1
Timepoint [3] 0 0
12hr and 24hr
Secondary outcome [4] 0 0
Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1
Timepoint [4] 0 0
12hr and 24hr
Secondary outcome [5] 0 0
Forced Vital Capacity (FVC)
Timepoint [5] 0 0
From predose to 25 hours postdose
Secondary outcome [6] 0 0
Area Under the Forced Vital Capacity (FVC) vs. Time Curve
Timepoint [6] 0 0
0-24 hours

Eligibility
Key inclusion criteria
* Diagnosis of moderate stable Chronic Obstructive Pulmonary.
* Disease with FEV1/FVC <0.7 at screening.
* Woman of non-childbearing potential.
* Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth control during the study and for at least 1 month after completion of study dosing.
* Female participants must not be breastfeeding.
* Men must agree to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after completion of study dosing.
* Current or past smoking history >10 pack-years.
* Must be capable of performing reproducible spirometry maneuvers.
Minimum age
40 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of significant respiratory disease other than COPD, and/ or requires daily long-term oxygen therapy.
* Exacerbation of COPD, lung infection within 6 weeks prior to study.
* Start of or change in dose of COPD treatment 4 weeks before study.
* Daily using of maintenance systemic/inhaled corticosteroids (>1000 microgram of fluticasone propionate equivalent or >5 mg prednisone).
* Use of bronchodilators or medication for the treatment of COPD, aspirin, anti-inflammatories for a specific time, prior to the first dose or is not willing to abstain from their use for the specified time periods prior to study dose administration.
* Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow angle glaucoma.
* Clinical significant hypersensitivity to medications.
* Participants have an uncontrolled hematologic, immunologic, renal, neurologic, hepatic, endocrine or other disease that may place participant at risk.
* Cerebrovascular, cardiovascular disease or abnormal ECG.
* History of drug or alcohol abuse.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2011
Sample size
Target
Accrual to date
Final
32
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Wellington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Mylan Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Theravance Biopharma
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and completed the follow-up assessments. During each of the four study periods, subjects were admitted to the clinic on Day -1 and housed overnight until after the last spirometry measurement. Serial pulmonary function tests were performed and PK (pharmacokinetics) samples collected up to 25 hours. Subjects were discharged from the clinic on Day 2 after evaluations.
Trial website
https://clinicaltrials.gov/study/NCT03064113
Trial related presentations / publications
Lo A, Borin MT, Bourdet DL. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2021 Mar;60(3):391-401. doi: 10.1007/s40262-020-00938-3.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Theravance Biopharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03064113